Document:

EX-10.9

 Exhibit 10.9 

 
 

 
 Personal & Confidential 
 August 1, 2011 
 Peter G. Edwards 
 16656 Anna’s Way 
 Chesterfield, MO 63005 

Dear Peter: 
 As you know, Covidien plc
(“Covidien”) is considering a spin-off of the Pharmaceuticals Segment of Covidien (“Segment”) resulting in the Segment becoming an independent, publicly-traded company or, alternatively, a sale of the Segment. Acknowledging your
importance to any Spin or Sale process and the ongoing operation of the Segment’s business, Covidien has selected you to be eligible for a special supplemental compensation program, the terms of which are described in this letter agreement
(“Agreement”). This Agreement is effective on the Effective Date and, unless Covidien extends this Agreement in writing, terminates on the Expiration Date if a Transaction has not been completed by the Expiration Date. Unless otherwise
defined in the text of this Agreement, capitalized terms used in this Agreement are defined in Section 9 below. 
 As a condition to
receiving any amounts described in this Agreement, you must (i) sign and return both copies of this Agreement to me no later than August 12, 2011, (ii) comply with the confidentiality provisions set forth in Section 6 of this
Agreement and the terms of the Covidien Guide to Business Conduct and (iii) meet all other applicable requirements under this Agreement. 
 1. Benefits in the Event of a Spin. In the event of a Spin, you will be eligible to receive the benefits described in this Section 1, subject to the provisions of Section 3. If you are
eligible for benefits pursuant to this Section 1, you shall not be eligible to receive any of the benefits described in Section 2 (“Benefits in the Event of a Sale”). 

(a) Spin Bonus. If the Company consummates a Spin and you remain in the continuous employment of SpinCo from the Spin Date through
the six (6) month anniversary of the Spin Date, the Company (or SpinCo, if so provided in the applicable separation or related agreement) shall pay to you a spin bonus equal to one hundred fifty seven thousand nine hundred fifty one dollars
($157,951) (USD) (“Spin Bonus”). If you are eligible to receive a Spin Bonus, the Company (or SpinCo, if applicable) shall pay such bonus to you as soon as administratively practicable after the six (6) month anniversary of the Spin
Date, but in no event later than ten (10) calendar days following such six (6) month anniversary date. If a Spin Bonus is payable pursuant to this Agreement, it shall be paid in a single lump sum payment, minus any applicable deductions or
withholdings or other reductions required by applicable law. By signing this Agreement, you expressly authorize the Company (or SpinCo, if applicable) to make any 

 
necessary deductions, withholdings, or other reductions from the Spin Bonus payment. If your employment with SpinCo terminates for any reason before the date the Spin Bonus is paid, you will not
be eligible to receive the Spin Bonus. 
 (b) Termination Bonus. If the Company consummates a Spin, you are employed with
SpinCo immediately following the Spin and your employment with SpinCo terminates under one of the circumstances described below before the date the Spin Bonus is paid, the Company (or SpinCo, if applicable) shall pay to you a termination bonus equal
to five hundred thousand dollars ($500,000) (USD) (“Termination Bonus”); provided, however, that your termination of employment is due to one of the following circumstances: (i) you resigned from employment with SpinCo for Good Reason
before the date the Spin Bonus is paid; (ii) your employment with SpinCo was involuntarily terminated by SpinCo without Cause before the date the Spin Bonus is paid; or (iii) your employment with SpinCo is terminated before the date the
Spin Bonus is paid due to your death or Permanent Disability. If any of these circumstances apply and you are eligible to receive a Termination Bonus, the Company (or SpinCo, if applicable) shall pay such bonus to you (or, in the case of your death,
to your estate) as soon as administratively practicable after your employment termination date, but in no event later than thirty (30) days after your employment termination date. If a Termination Bonus is payable pursuant to this Agreement, it
shall be paid in a single lump sum payment, minus any applicable deductions or withholdings or other reductions required by applicable law. By signing this Agreement, you expressly authorize the Company (or SpinCo, if applicable) to make any
necessary deductions, withholdings, or other reductions from the Termination Bonus payment. 
 2. Benefits in the Event of a Sale. In the
event of a Sale, you will be eligible to receive the benefits described in this Section 2, subject to the provisions of Section 3. If you are eligible for benefits pursuant to this Section 2, you shall not be eligible to receive any
of the benefits described in Section 1 (“Benefits in the Event of a Spin”). 
 (a) Sale Bonus. 

(i) Subject to Subsection 2(a)(ii), the Company (or the Purchaser, if so provided in the purchase and sale agreement) shall pay to you a
sale bonus equal to five hundred thousand dollars ($500,000) (USD) (“Sale Bonus”) as soon as administratively practicable after the six (6) month anniversary of the Sale Date, but in no event later than ten (10) calendar days
following such six (6) month anniversary date. If a Sale Bonus is payable pursuant to this Agreement, it shall be paid in a single lump sum payment, minus any applicable deductions or withholdings or other reductions required by applicable law.
By signing this Agreement, you expressly authorize the Company (or the Purchaser, if applicable) to make any necessary deductions, withholdings, or other reductions from the Sale Bonus payment. 

(ii) In order to receive the Sale Bonus, you must be actively employed by the Purchaser on the date the Sale Bonus is paid; provided,
however, that if you are not actively employed by the Purchaser on the date that the Sale Bonus is paid and one of the following circumstances applies then the Company (or the Purchaser, if applicable) shall pay to you the Sale Bonus: (A) the
Company involuntarily terminated your employment without Cause after the signing of an agreement, the consummation of which would constitute the Sale, and before the 

  
 2/9

 
Sale Date; (B) you remained employed with the Company through immediately prior to the Sale but did not become an employee of the Purchaser immediately upon the consummation of the Sale and
you did not receive an Offer of Comparable Employment from the Purchaser; (C) you became an employee of the Purchaser immediately upon the Sale Date, but you resigned from employment with the Purchaser for Good Reason or were involuntarily
terminated by the Purchaser without Cause before the date the Retention Bonus is paid; or (D) you became an employee of the Purchaser immediately upon the Sale Date, but your employment with the Purchaser is terminated before the date the Sale
Bonus is paid due to your death or Permanent Disability. If any of these circumstances apply, then the Company (or the Purchaser, if applicable) shall pay the Sale Bonus to you (or, in the case of your death, to your estate) as soon as
administratively practicable after the Sale Date (in the case of (A) or (B) above) or your employment termination date (in the case of (C) or (D) above), but in no event later than thirty (30) days after the Sale Date or
your employment termination date, as applicable. 
 (b) Severance Benefits. If, on or after the Sale
Date, but before the one year anniversary of the Sale Date, your employment with Purchaser is involuntarily terminated under circumstances that, had the Company terminated your employment while you were in employment with the Company, would have
entitled you to severance benefits under an applicable Company severance plan as in effect on the Sale Date (“Covidien Severance Plan”), and the severance benefits, if any, provided by the Purchaser are not at least equal to the severance
benefits which you would have received under the Covidien Severance Plan had it applied, then the Company shall provide to you the difference between the severance benefits payable by Purchaser and the severance benefits provided for under the
Covidien Severance Plan. The Company shall provide these benefits to you in a single lump sum payment as soon as administratively practicable following your employment termination date, but in any event not later than March 15th of the year following the year in which your employment termination
date occurs. If the Purchaser provides severance benefits which equal or exceed the severance benefits provided for under the Covidien Severance Plan, then the Company shall have no obligation whatsoever with respect to such benefits. 

3. General Conditions. In order to be eligible to receive any benefits under this Agreement, you must be actively employed by the Company and
providing services to the Segment on the Transaction Date and you must satisfy any other condition set forth in this Agreement. You will not be eligible to receive any benefits under this Agreement under any of the following circumstances:
(a) your employment with the Company terminates for any reason before the Transaction Date (including a voluntary termination and a termination due to death or Permanent Disability) other than, only to the extent described herein, an
involuntary termination without Cause; (b) you cease providing services to the Segment before the Transaction Date either as a result of a transfer of your employment within the Company or the reassignment of your duties to a segment of the
Company other than the Segment; (c) the Transaction Date does not occur before the Expiration Date; or (d) the Company determines that you violated either the confidentiality provisions set forth in Section 6 of this Agreement or any
provision of the Covidien Guide to Business Conduct at any time. 
 4. Termination for Cause; Breach of Obligations. Notwithstanding any
other provision of this Agreement to the contrary, you shall not be entitled to receive any payments under this 

  
 3/9

 
Agreement (including, but not limited to, the Retention Bonus Payments, the Spin Bonus, the Sale Bonus and the Termination Bonus) if the Company, Purchaser or SpinCo, as applicable, terminates
your employment for Cause. You agree and recognize that should you breach any of the obligations or covenants set forth in this Agreement, the Company, Purchaser or SpinCo, as applicable, will have no further obligation to provide you with any of
the benefits provided for herein, and will have the right to seek repayment of all consideration paid pursuant to this Agreement up to the time of any such breach. Further, by signing this Agreement, you acknowledge that, in the event of a breach by
you of this Agreement, the Company, Purchaser, or SpinCo, as applicable, may seek any and all appropriate relief for any such breach, including equitable relief and/or money damages, attorney’s fees and costs. If it is discovered at any time
that you engaged in behavior during employment with the Company, Purchaser or SpinCo that would have justified termination for Cause, then, at the Company’s election, any consideration payable to you under this Agreement shall immediately cease
and you shall be required to return any consideration paid under this Agreement to the entity which paid it to you. The Company, Purchaser or SpinCo, as applicable, may withhold paying any further consideration pending resolution of an inquiry that
could lead to a finding that you engaged in such behavior. 
 5. Outstanding Equity Awards. The Sale shall be considered a
“Divestiture” under the award certificate applicable to equity awards over Covidien ordinary shares that are outstanding on the Sale Date. Any rights that you may have at the time of a Transaction with respect to any equity award
(including stock options, restricted units and performance units) granted to you by Covidien (or over Covidien ordinary shares) will be governed by the terms of the plan document under which such award was issued, the accompanying award certificate
and any operative agreement pursuant to which a Transaction is effectuated. By signing this Agreement, you hereby acknowledge and understand that nothing in this Agreement provides for accelerated vesting or other preferential treatment of any
equity award over Covidien ordinary shares and that any rights to vesting or exercisability are governed in all respects by the terms of the applicable plan, award certificate and operative agreement pursuant to which a Transaction is effectuated.

 6. Confidentiality. 
 (a) Except as required by any court or governmental entity, by signing this Agreement, you agree not to disclose or discuss with any person, except for your spouse (or domestic partner) and legal counsel,
for a period commencing on the date hereof and until the one year anniversary of the Transaction Date (regardless of the termination of this Agreement) the existence or terms of this Agreement, the fact that the Transaction is being considered, the
terms or conditions of the Transaction or the status of any Transaction discussions or negotiations; provided, however, that (i) you are free to consult with designated officers and other representatives of Covidien and/or the Segment business
or with Covidien legal counsel (both in-house and outside counsel), accountants, financial and other advisors representing Covidien in connection with the Transaction; and (ii) as expressly permitted by Covidien’s Senior Vice President and
General Counsel in writing, you may disclose such matters to, and discuss such matters with, prospective buyers. 

  
 4/9

 (b) By signing this Agreement, you also agree that you will not provide (and have not
provided) any Confidential Information to any prospective buyer or any third party (including any investment bank) or other persons in connection with any proposed Transaction without the express prior written consent or approval of Covidien’s
Senior Vice President and General Counsel. This provision should be considered in addition to any other obligation you have to protect Confidential Information, including without limitation, disclosure of any proprietary or confidential information
to any third party, competitor or potential competitor, or use of such information for any purpose other than the benefit of the Company. 
 7.
Cooperation in Transaction Efforts. An investment banking firm may be hired as an agent to help the Company effectuate the Transaction. As part of the process, an investment banking firm may be working with you and requiring your assistance
in order to complete a successful Transaction. You agree to use your best efforts to cooperate with such investment banking firm and Covidien’s senior management as they negotiate the Transaction and, notwithstanding the confidentiality
provisions of this Agreement, you are hereby permitted to so cooperate with representatives of such investment banking firm, as specifically designated by Covidien’s Senior Vice President and General Counsel. You also agree not to take any
action which would favor or give any advantage to any one or more potential buyers, other than as specifically instructed by Covidien’s Senior Vice President and General Counsel, and agree to promote a Transaction and answer inquiries regarding
a Transaction truthfully, to the best of your ability and consistent with your duty to act in the best interests of the Company. In addition, you agree to review the documents regarding the proposed Transaction before they are executed, particularly
all representations and warranties made by the Company or their designees about the Segment’s business, and, if requested by Covidien’s Senior Vice President and General Counsel, to certify in writing that there are no material
misstatements or omissions with respect to matters to which you have personal knowledge, if indeed that is the case. Your failure to comply with the terms of this Agreement and/or other Company policies including, but not limited to, the Covidien
Guide to Business Conduct, may lead to discipline up to and including termination of employment. 
 8. Effect on Benefit Plans. No
amounts payable pursuant to this Agreement shall constitute wages or compensation for purposes of determining the amount of any benefits (including, without limitation, severance benefits) you are or may be entitled to receive at any time from or
under any employee benefit plan, program or arrangement maintained or contributed to by the Company. 
 9. Definitions. For purposes of
this Agreement, the following terms shall have the meanings ascribed to them. 
 (a) “Cause” means (i) the
substantial failure or refusal to perform duties and responsibilities of your job as required by the Company (or, following a Sale, Purchaser; or, following a Spin, SpinCo), (ii) a violation of any fiduciary duty owed to the Company (or,
following a Sale, Purchaser; or, following a Spin, SpinCo), (iii) the conviction of a felony or misdemeanor, (iv) dishonesty, (v) theft, (vi) any violation of Company (or, following a Sale, Purchaser; or, following a Spin,
SpinCo) rules or policy, or (vii) any other egregious conduct, that has or could have a serious and detrimental impact on the Company (or, following a Sale, 

  
 5/9

 
Purchaser; or, following a Spin, SpinCo) and its employees. Prior to a Transaction, and on or following a Transaction in circumstances which could affect obligations of the Company,
Covidien’s Senior Vice President, Human Resources, in his sole and absolute discretion, shall determine whether Cause exists. Examples of “Cause” may include, but are not limited to, excessive absenteeism, misconduct, insubordination,
violation of Company (or, following a Sale, Purchaser; or, following a Spin, SpinCo) policy, dishonesty, and deliberate unsatisfactory performance (e.g., employee refuses to improve deficient performance). 

(b) “Company” means Covidien and all of its subsidiaries and affiliates. 

(c) “Confidential Information” means all information (whether or not specifically labeled or identified as confidential), in
any form or medium (including digital media) that is disclosed to, or developed or learned by you in the performance of your duties for the Company and that relates to the business, operation, finances, products, services, and research and
development of the Segment and/or the Company or its respective suppliers, customers or clients, including, without limitation: (i) information relating to strategic and staffing plans and practices, business, marketing, promotional or sales
plans, practices and programs, costs, pricing structures, and accounting practices; (ii) identities of, individual requirements of, specific contractual arrangements with, and information about, such suppliers, clients and customers and their
confidential information; (iii) compilations of data and analyses, processes, formulae, methods, techniques, systems, research, records, reports, manuals, documentation, models, data and data bases relating thereto; (iv) computer software
(including, without limitation, operating systems and applications), documentations, data and data bases; (v) inventions, designs, developments, devices, methods and processes (whether or not patentable or reduced to practice), and
(vi) any other information covered by any Company policy or agreement regarding confidential, trade secret or proprietary information. On and following a Sale, Confidential Information shall mean, in addition to the information described in
this paragraph, the information which would be described in this paragraph if “the Company” were replaced by “Purchaser” each time it appears in this paragraph. On and following a Spin, Confidential Information shall mean, in
addition to the information described in this paragraph, the information which would be described in this paragraph if “the Company” were replaced by “SpinCo” each time it appears in this paragraph. 

(d) “Effective Date” means August 1, 2011. 
 (e) “Expiration Date” means the second anniversary of the Effective Date. 
 (f) “Good Reason” means (i) any material reduction in your base salary or target bonus opportunity as in effect immediately before the Transaction Date, (ii) the assignment to you of
duties which are materially inconsistent with the duties you performed immediately before the Transaction Date or the changing of your position (including changes in reporting relationships and level) which are materially adverse in comparison to
your position immediately before the Transaction Date, (iii) a material reduction in the aggregate value of your long-term incentive opportunity and employee benefits as in effect immediately before the Transaction Date provided, however, that
the actions in each of (i), (ii), and (iii) above will not be considered Good Reason unless (A) you describe the basis for the events, circumstances, or conditions 

  
 6/9

 
alleged by you to constitute grounds for Good Reason in reasonable detail in a written notice provided to Purchaser or SpinCo, as applicable, within thirty (30) calendar days of your
knowledge of such events, circumstances, or conditions alleged to constitute Good Reason, (B) Purchaser or SpinCo, as applicable, has failed to cure such events, circumstances, or conditions within thirty (30) calendar days of receiving
such written notice and (C) you terminate your employment not later than ten (10) days following the expiration of the period described in clause (B). 
 (g) “Offer of Comparable Employment” means an offer of employment, or a confirmation of continued employment, that provides you with (i) the same or higher base salary and target bonus
opportunity that were in effect immediately before the Sale Date; and (ii) a work location that is no more than fifty (50) miles from your work location immediately before the Sale Date. 

(h) “Permanent Disability” means that you have a permanent and total incapacity from engaging in any employment for the
Company, Purchaser, or SpinCo, as applicable, for physical or mental reasons. A “Permanent Disability” shall be deemed to exist if you meet the requirements for disability benefits under the Company’s, Purchaser’s or
SpinCo’s, as applicable, long-term disability plan or under the requirements for disability benefits under the Social Security law then in effect, or if you are designated with an inactive employment status at the end of a disability or medical
leave. 
 (i) “Purchaser” means an entity which does not control, and is not controlled by or under common control
with, Covidien, and which is the purchaser in the Sale, including for this purpose more than one such entity acting in concert to engage in the Sale. 
 (j) “Sale” means the sale of all or substantially all (measured as at least eighty percent (80%) of market value) of the assets of the Segment to a Purchaser. 

(k) “Sale Date” means the closing date of the Sale. 
 (l) “Spin” means a separation of the Segment from the Company through a pro-rata distribution of the equity of SpinCo to Covidien’s shareholders, or a similar transaction which is
determined in writing by Covidien’s Senior Vice President, Human Resources, to be a Spin. 
 (m) “SpinCo” means
the business entity which directly and/or indirectly holds the assets constituting the Segment immediately prior to the Spin, the equity of which is distributed to Covidien’s shareholders in the Spin. 

(n) “Spin Date” means the closing date of the Spin. 
 (o) “Transaction” means a Sale or Spin, as applicable. 
 (p)
“Transaction Date” means the Sale Date or Spin Date, as applicable. 

  
 7/9

 10. Interpretation of the Agreement. Covidien’s Senior Vice President, Human Resources has the
discretionary authority to interpret the terms of this Agreement and resolve any disputes that may arise hereunder including, but not limited to, whether behavior by you constitutes Cause and the amount of any payments due to you under this
Agreement. Any determinations made by Covidien’s Senior Vice President, Human Resources hereunder shall be final and binding on all parties. 
 11. Legal Remedy. You acknowledge that a remedy at law for any breach or threatened breach of this Agreement would be inadequate and, therefore, you agree that the Company, Purchaser and SpinCo as
applicable, shall be entitled to injunctive relief, both preliminary and permanent, in addition to any other available rights and remedies in case of any such breach or threatened breach. In the event of any action arising from or relating to this
Agreement, the party substantially prevailing shall recover its costs, including reasonable attorneys’ fees. 
 12. Choice of Law.
This Agreement shall be governed by the laws of the Commonwealth of Massachusetts, without reference to rules in respect of conflicts of laws. 

13. Assignment; Successor. Neither this Agreement nor any rights or obligations created herein may be assigned or delegated by you. Tyco
Healthcare Group LP is entering into this agreement on behalf of the Company and it may assign any rights and obligations it has under this Agreement to any Covidien subsidiary or affiliate without your consent, but shall remain liable for any
payments provided hereunder that are not timely made by any such assignee. This Agreement shall be binding on any successor of the Company, and Covidien may and shall cause this Agreement to be binding on Purchaser (in the case of a Sale) or SpinCo
(in the case of a Spin) if, and to the extent, necessary to ensure that the benefits promised hereunder are paid or provided as described herein. 
 14. Severability. If any provision of this Agreement is declared invalid, illegal or unenforceable by any court of competent jurisdiction, all of the remaining provisions of this Agreement shall
continue in full force and effect. 
 15. Complete Agreement. Except as otherwise provided herein, this Agreement is the complete
agreement between you and the Company with respect to the subject matter contained in the Agreement and will supersede or replace all prior retention agreements or understandings between the parties, including the letter agreements dated
December 8, 2010 and February 25, 2011, by and between you and the Company. 
 16. Compliance with Internal Revenue Code
Section 409A. The Company (but, without your written consent, not Purchaser or SpinCo) shall have the right to modify the timing and/or the method of payment of any amounts payable under this Agreement if such modification is necessary in
order to avoid the imposition of the penalty tax under Internal Revenue Code Section 409A (“Section 409A”), but only to the minimum extent necessary to avoid such penalty tax. Notwithstanding the above, in the event that you are a
“specified employee” (within the meaning of Section 409A and with such classification to be determined in accordance with the methodology established by the applicable employer), amounts and benefits that are deferred compensation
(within the meaning of Section 409A) that would otherwise be payable or 

  
 8/9

 
provided under this Agreement during the six (6) month period immediately following your employment termination date shall instead be paid, without interest, on the first business day after
the date that is six (6) months following such termination date; provided, however, that if you die following the such termination date and prior to the payment of the any amounts delayed on account of Section 409A, such amounts shall be
paid to the personal representative of your estate within thirty (30) calendar days after the date of your death. Each payment under this Agreement shall be treated as a separate payment for purposes of Section 409A. In no event may you,
directly or indirectly, designate the calendar year of any payment to be made under this Agreement. In no event shall a termination of employment occur for purposes of this Agreement until you experience a “separation from service” within
the meaning of Section 409A, to the extent necessary to avoid the imposition of the penalty tax under Section 409A. 
 17. No
Commitment. Nothing in this Agreement shall, or shall be construed to, subject the Company to any legal obligation of any kind whatsoever, under any theory of contract, detrimental reliance, fraud or otherwise, to cause a Transaction.

 18. Amendments. No modification or amendment hereof shall be valid or binding on either party unless made in writing and signed by
both parties or by their duly authorized officers or representatives. 
 Please review this Agreement carefully. As a key management employee of
the Segment, we certainly appreciate your efforts and the important role that you play in assuring that the Transaction is a success. 

Sincerely, 
  

	
	 /s/ Michael P. Dunford

	 Michael P. Dunford

	 Senior Vice President, Human Resources

 If you are in agreement with the above and foregoing, please signify your acceptance by signing and dating both copies of
this Agreement in the spaces below and returning both to me no later than August 12, 2011. 
  

									
	 Signature:
	 	 /s/ Peter Edwards
	  		  	Date:	 	    8/11/11

									
					
	 Printed Name:
	 	Peter Edwards	  		  		 	

  
 9/9EX-10.13

 Exhibit 10.13 
 DEED OF INDEMNIFICATION 
 THIS DEED OF INDEMNIFICATION (this
“Agreement”), dated as of                  , is made by and between Mallinckrodt plc, an Irish public limited company, and (“Indemnitee”).

 WHEREAS, it is essential to Mallinckrodt plc to retain and attract as directors and secretary the most capable persons
available; 
 WHEREAS, Indemnitee is a director or secretary of Mallinckrodt plc; 

WHEREAS, each of Mallinckrodt plc and Indemnitee recognize the increased risk of litigation and other claims currently being asserted
against directors and officers of companies; 
 WHEREAS, in recognition of Indemnitee’s need for (i) substantial
protection against personal liability, (ii) specific contractual assurance that such protection will be available to Indemnitee (regardless of, among other things, any amendment to or revocation of Mallinckrodt plc’s Articles of
Association or any change in the composition of Mallinckrodt plc’s Board of Directors or acquisition transaction relating to Mallinckrodt plc), Mallinckrodt plc wishes to provide in this Agreement for the indemnification by Mallinckrodt plc of
Indemnitee as set forth in this Agreement, and, to the extent insurance is maintained, to provide for the continued coverage of Indemnitee under Mallinckrodt plc’s directors’ and officers’ liability insurance policies as set forth in
this Agreement; 
 NOW, THEREFORE, in consideration of the above premises and of Indemnitee continuing to serve Mallinckrodt plc
directly or, at its request, with another Enterprise, and intending to be legally bound hereby, the parties agree as follows: 
 1. Certain
Definitions. 
 (a) Affiliate: any corporation or other person or entity that directly, or indirectly through one or more
intermediaries, controls or is controlled by, or is under common control with, the person specified. 
  

	(b)	Board: the Board of Directors of Mallinckrodt plc. 

  

	(c)	Change in Control: shall be deemed to have occurred if: 

 (i) any “person,” as such term is used in Sections 3(a)(9) and 13(d) of the Exchange Act, becomes a “beneficial owner,” as such term is used in Rule 13d-3 promulgated under the
Exchange Act, of 50% or more of the Voting Shares (as defined below) of Mallinckrodt plc; 
 (ii) the majority of the Board
consists of individuals other than Incumbent Directors, which term means the members of the Board as of the execution hereof, provided that any person becoming a director subsequent to such time whose election or nomination for election was
supported by three-quarters of the directors who immediately prior to such election or nomination for election comprised the Incumbent Directors shall be considered to be an Incumbent Director; 

 (iii) Mallinckrodt plc adopts any plan of liquidation providing for the distribution of all
or substantially all of its assets; 
 (iv) all or substantially all of the assets or business of Mallinckrodt plc is disposed
of pursuant to a merger, consolidation or other transaction (unless the shareholders of Mallinckrodt plc immediately prior to such a merger, consolidation or other transaction beneficially own, directly or indirectly, in substantially the same
proportion as they owned the Voting Shares of Mallinckrodt plc, all of the Voting Shares or other ownership interests of the entity or entities, if any, that succeed to the business of Mallinckrodt plc); or 

(v) Mallinckrodt plc combines with another company and is the surviving entity but, immediately after the combination, the shareholders
of Mallinckrodt plc immediately prior to the combination hold, directly or indirectly, 50% or less of the Voting Shares of the combined company (there being excluded from the number of shares held by such shareholders, but not from the Voting Shares
of the combined company, any shares received by Affiliates of such other company in exchange for shares of such other company), provided, however, that any occurrence that would, in the absence of this proviso, otherwise constitute a Change in
Control pursuant to any of clause (i), (iii), (iv) or (v) above, shall not constitute a Change in Control if such occurrence is approved by a majority of the directors on the Board who were directors immediately prior to such occurrence.

 (d) Enterprise: Mallinckrodt plc and any other corporation, limited liability company, partnership, joint venture, trust, employee
benefit plan or other enterprise of which Indemnitee is or was serving at the request of Mallinckrodt plc as a director, officer, secretary, trustee, general partner, managing member, fiduciary, board of directors’ committee member, employee or
agent. 
 (e) Exchange Act: the U.S. Securities Exchange Act of 1934, as amended. 

(f) Expenses: any expense, liability, or loss, including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties, amounts paid or
to be paid in settlement, any interest, assessments, or other charges imposed thereon, any federal, state, local, or foreign taxes imposed as a result of the actual or deemed receipt of any payments under this Agreement, and all other costs and
obligations, paid or incurred in connection with investigating, defending, prosecuting (subject to Section 2(b)), being a witness in, participating in (including on appeal), or preparing for any of the foregoing in, any Proceeding relating to
any Indemnifiable Event. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond,
or other appeal bond or its equivalent. 
 (g) Indemnifiable Event: any event or occurrence that takes place either prior to or after the
execution of this Agreement, related to the fact that Indemnitee is or was a director, officer, secretary or employee of Mallinckrodt plc, or while a director or secretary of Mallinckrodt plc is or was serving at the request of Mallinckrodt plc as a
director, officer, secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise, or related to anything done or
not done by Indemnitee in any such capacity, whether or not the basis of the Proceeding is alleged action in an official capacity as a director, officer, secretary, employee, trustee, agent, or fiduciary or in any other capacity while serving as a
director, officer, secretary, employee, trustee, agent, or fiduciary. 

  
 - 2 -

 (h) Independent Counsel: the meaning specified in Section 3. 

(i) Proceeding: any threatened, pending, or completed action, suit, or proceeding or any alternative dispute resolution mechanism (including an
action by or in the right of Mallinckrodt plc), or any inquiry, hearing, or investigation, whether conducted by Mallinckrodt plc or any other party, that Indemnitee in good faith believes might lead to the institution of any such action, suit, or
proceeding, whether civil, criminal, administrative, investigative, or other. 
 (j) Reviewing Party: the meaning specified in
Section 3. 
 (k) Voting Shares: shares of any class or classes having general voting power under ordinary circumstances, in the
absence of contingencies, to elect the directors (or similar function) of an Enterprise. 
 2. Agreement to Indemnify. 

(a) General Agreement. In the event Indemnitee was, is, or becomes a party to or witness or other participant in, or is threatened to be made a
party to or witness or other participant in, a Proceeding by reason of (or arising in part out of) an Indemnifiable Event, Mallinckrodt plc shall indemnify Indemnitee from and against any and all Expenses to the fullest extent permitted by law, as
the same exists or may hereafter be amended or interpreted (but in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits Mallinckrodt plc to provide broader indemnification rights than
were permitted prior thereto). For the purposes of this Agreement, the meaning of the phrase “to the fullest extent permitted by law” shall include, but not be limited to: (i) to the fullest extent permitted by the provisions of Irish
law and/or the Articles of Association of Mallinckrodt plc that authorize, permit or contemplate indemnification by agreement, court action or corresponding provisions of any amendment to or replacement of such provisions; and (ii) to the
fullest extent authorized or permitted by any amendments to or replacements of Irish law and/or the Articles of Association of Mallinckrodt plc adopted after the date of this Agreement that increase the extent to which a company may indemnify its
directors or secretary. 
 (b) Initiation of Proceeding. Notwithstanding anything in this Agreement to the contrary, Indemnitee shall not
be entitled to indemnification pursuant to this Agreement in connection with any Proceeding initiated by Indemnitee against Mallinckrodt plc or any of its subsidiaries or any director, officer or employee of Mallinckrodt plc or any of its
subsidiaries unless (i) Mallinckrodt plc has joined in or the Board has consented to the initiation of such Proceeding; (ii) the Proceeding is one to enforce indemnification rights under Section 4; or (iii) the Proceeding is
instituted after a Change in Control and Independent Counsel has approved its initiation. 
 (c) Mandatory Indemnification.
Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in defense of any Proceeding relating in whole or in part to an Indemnifiable Event or in defense of any issue or
matter therein, Indemnitee shall be indemnified by Mallinckrodt plc hereunder against all Expenses incurred in connection therewith. 

  
 - 3 -

 (d) Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to
indemnification by Mallinckrodt plc for some or a portion of Expenses, but not, however, for the total amount thereof, Mallinckrodt plc shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. 

(e) Prohibited Indemnification. No indemnification pursuant to this Agreement shall be paid by Mallinckrodt plc: 

(i) on account of any Proceeding in which a final and non-appealable judgment is rendered against Indemnitee for an accounting of profits
made from the purchase or sale by Indemnitee of securities of Mallinckrodt plc pursuant to the provisions of Section 16(b) of the Exchange Act or similar provisions of any federal, state, or local laws; 

(ii) if a court of competent jurisdiction by a final and non-appealable judgment, shall determine that such indemnification is not
permitted under applicable law; 
 (iii) on account of any Proceeding relating to an Indemnifiable Event as to which the
Indemnitee has been convicted of a crime constituting a felony under the laws of the jurisdiction where the criminal action had been brought (or, where a jurisdiction does not classify any crime as a felony, a crime for which Indemnitee is sentenced
to death or imprisonment for a term exceeding one year); or 
 (iv) on account of any Proceeding brought by Mallinckrodt plc or
any of its subsidiaries against Indemnitee. 
 3. Reviewing Party; Exhaustion of Remedies.

(a) Prior to any Change in Control, the reviewing party (the “Reviewing Party”) shall be any appropriate person or body consisting of a member
or members of the Board or any other person or body appointed by the Board who is not a party to the particular Proceeding with respect to which Indemnitee is seeking indemnification; after a Change in Control, the Independent Counsel referred to
below shall become the Reviewing Party. With respect to all matters arising after a Change in Control concerning the rights of Indemnitee to indemnity payments and Expense advances under this Agreement, the Indemnification Agreement, dated as of the
date hereof, between Mallinckrodt Brand Pharmaceuticals, Inc., a Delaware corporation (“Brand Pharma”), and Indemnitee (the “Brand Pharma Indemnification Agreement”) or any other agreement to which Mallinckrodt plc or any of its
Affiliates is a party or under applicable law, Mallinckrodt plc’s Articles of Association or the certificate of incorporation or bylaws of Brand Pharma (the “Brand Pharma Organizational Documents”) now or hereafter in effect relating
to indemnification for Indemnifiable Events, Mallinckrodt plc and Brand Pharma shall seek legal advice only from independent counsel (“Independent Counsel”) selected by Indemnitee and approved by Mallinckrodt plc (which approval shall not
be unreasonably withheld), and who has not otherwise performed services for Mallinckrodt plc, Brand Pharma or the Indemnitee (other than in connection with indemnification matters) within the last five years. The Independent Counsel shall not
include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing Mallinckrodt plc, Brand Pharma or Indemnitee in an action to determine Indemnitee’s rights under
this Agreement. Such counsel, among other 

  
 - 4 -

 
things, shall render its written opinion to Mallinckrodt plc, Brand Pharma and Indemnitee as to whether and to what extent the Indemnitee should be permitted to be indemnified under applicable
law. In doing so, the Independent Counsel may consult with (and rely upon) counsel in any appropriate jurisdiction who would qualify as Independent Counsel (“Local Counsel”). To the fullest extent permitted by law, Mallinckrodt plc agrees
to pay the reasonable fees of the Independent Counsel and the Local Counsel and to indemnify fully such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, loss, and damages arising out of or relating to this
Agreement or the engagement of Independent Counsel or the Local Counsel pursuant hereto. 
 (b) The Brand Pharma Indemnification Agreement
provides that, prior to making written demand on Brand Pharma for indemnification pursuant to Section 4(a) of the Brand Pharma Indemnification Agreement or making a request for Expense Advance (as defined in the Brand Pharma Indemnification
Agreement) pursuant to Section 2(c) of the Brand Pharma Indemnification Agreement, Indemnitee shall (i) seek such indemnification or Expense Advance, as applicable, under any applicable insurance policy and (ii) request that
Mallinckrodt plc consider in its discretion whether to make such indemnification or Expense Advance, as applicable. Upon any such request by Indemnitee of Mallinckrodt plc, Mallinckrodt plc shall consider whether to make such indemnification or
Expense Advance, as applicable, based on the facts and circumstances related to the request. Mallinckrodt plc may require, as a condition to making any indemnification or Expense Advance, as applicable, that Indemnitee enter into an agreement
providing for such indemnification or Expense Advance, as applicable, to be made subject to substantially the same terms and conditions applicable to an indemnification or Expense Advance, as applicable, by Brand Pharma under the Brand Pharma
Indemnification Agreement (including, without limitation, conditioning any Expense Advance upon delivery to Mallinckrodt plc of an undertaking of the type described in clause (i) of the proviso to Section 2(c) of the Brand Pharma
Indemnification Agreement). 
 4. Indemnification Process and Appeal. 
 (a) Indemnification Payment. Indemnitee shall be entitled to indemnification of Expenses, and shall receive payment thereof, from Mallinckrodt plc in accordance with this Agreement as soon as
practicable after Indemnitee has made written demand on Mallinckrodt plc for indemnification, unless the Reviewing Party has given a written opinion to Mallinckrodt plc that Indemnitee is not entitled to indemnification under applicable law.

 (b) Adjudication or Arbitration. (i) Regardless of any action by the Reviewing Party, if Indemnitee has not received full
indemnification to which Indemnitee is entitled hereunder within thirty days after making a demand or request in accordance with Section 4(a) (a “Nonpayment”), Indemnitee shall have the right to enforce its indemnification rights
under this Agreement by commencing litigation in any court located in the country of Ireland (an “Irish Court”) having subject matter jurisdiction thereof seeking an initial determination by the court or by challenging any determination by
the Reviewing Party or any aspect thereof. Any determination by the Reviewing Party not challenged by Indemnitee in any such litigation shall be binding on Mallinckrodt plc, Brand Pharma and Indemnitee. The remedy provided for in this Section 4
shall be in addition to any other remedies available to Indemnitee at law or in equity. Mallinckrodt plc, Brand Pharma and Indemnitee hereby irrevocably and unconditionally (A) consent to submit to

  
 - 5 -

 
the non-exclusive jurisdiction of the Irish Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (B) waive any objection to the laying of venue
of any such action or proceeding in the Irish Court, and (C) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Irish Court has been brought in an improper or inconvenient forum. For the
avoidance of doubt, nothing in this Agreement shall limit any right Indemnitee may have under applicable law to bring any action or proceeding in any other court. 
 (ii) Alternatively, in the case of a Nonpayment, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of
the American Arbitration Association. 
 (iii) In the event that a determination shall have been made pursuant to
Section 4(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 4(b) shall be conducted in all respects as a de novo trial, or arbitration,
on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 4(b) Mallinckrodt plc shall have the burden of proving Indemnitee is not
entitled to indemnification. 
 (iv) In the event that Indemnitee, pursuant to this Section 4(b), seeks a judicial
adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Agreement, and it is determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive all of the
indemnification sought, Indemnitee shall be entitled to recover from Mallinckrodt plc, and shall be indemnified by Mallinckrodt plc against, any and all Expenses actually and reasonably incurred by him in such judicial adjudication or arbitration.
If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification sought, the Indemnitee shall be entitled to recover from Mallinckrodt plc, and shall be indemnified
by Mallinckrodt plc against, any and all Expenses reasonably incurred by Indemnitee in connection with such judicial adjudication or arbitration. 
 (c) Defense to Indemnification, Burden of Proof, and Presumptions. (i) It shall be a defense to any action brought by Indemnitee against Mallinckrodt plc to enforce this Agreement that it is
not permissible under applicable law for Mallinckrodt plc to indemnify Indemnitee for the amount claimed. 
 (ii) In connection
with any action or any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder, the burden of proving such a defense or determination shall be on Mallinckrodt plc. 

(iii) Neither the failure of the Reviewing Party to have made a determination prior to the commencement of such action by Indemnitee that
indemnification of the Indemnitee is proper under the circumstances because Indemnitee has met the standard of conduct set forth in applicable law, nor an actual determination by the Reviewing Party that the Indemnitee had not met such applicable
standard of conduct, shall, of itself, be a defense to the action or create a presumption that the Indemnitee has not met the applicable standard of conduct. 

  
 - 6 -

 (iv) For purposes of this Agreement, to the fullest extent permitted by law, the termination
of any claim, action, suit, or proceeding, by judgment, order, settlement (whether with or without court approval), conviction, or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did not
meet any particular standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law. 
 (v) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of any Enterprise,
including financial statements, or on information supplied to Indemnitee by the management of such Enterprise in the course of their duties, or on the advice of legal counsel for such Enterprise or on information or records given or reports made to
such Enterprise by an independent certified public accountant or by an appraiser or other expert selected by such Enterprise. The provisions of this Section 4(c)(v) shall not be deemed to be exclusive or to limit in any way the other
circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in applicable law. 
 (vi) The knowledge and/or actions, or failure to act, of any other director, trustee, partner, managing member, fiduciary, officer, agent or employee of any Enterprise shall not be imputed to Indemnitee
for purposes of determining any right to indemnification under this Agreement. 
 (vii) Mallinckrodt plc shall be precluded from
asserting in any judicial proceeding or arbitration commenced pursuant to this Agreement that the procedures or presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any court or before any arbitrator that
Mallinckrodt plc is bound by all the provisions of this Agreement. 
 5. Indemnification for Expenses Incurred in Enforcing Rights. In
addition to Indemnitee’s rights under Section 4(b)(iv), Mallinckrodt plc shall indemnify Indemnitee against any and all Expenses that are incurred by Indemnitee in connection with any action brought by Indemnitee: 

(a) for indemnification or advance payment of Expenses under any agreement to which Mallinckrodt plc or any of its Affiliates is a party (other than this
Agreement) or under applicable law, Mallinckrodt plc’s Articles of Association or the Brand Pharma Organizational Documents now or hereafter in effect relating to indemnification or advance payment of Expenses for Indemnifiable Events (it being
specified, for the avoidance of doubt, that this clause (a) shall not be deemed to provide Indemnitee with a right to the indemnification or advance payment of Expenses being sought in such action), and/or 

(b) for recovery under directors’ and officers’ liability insurance policies maintained by Mallinckrodt plc, 

but, in either case, only in the event that Indemnitee ultimately is determined to be entitled to such indemnification or expense advance or insurance
recovery, as the case may be. 
 6. Notification and Defense of Proceeding. 
 (a) Notice. Promptly after receipt by Indemnitee of notice of the commencement of any Proceeding, Indemnitee shall, if a claim in respect thereof is to be made against Mallinckrodt plc under this
Agreement, notify Mallinckrodt plc and Brand Pharma of the commencement thereof; but the omission so to notify Mallinckrodt plc and Brand Pharma will not relieve Mallinckrodt plc from any liability that it may have to Indemnitee, except as provided
in Section 6(c). 

  
 - 7 -

 (b) Defense. With respect to any Proceeding as to which Indemnitee notifies Mallinckrodt plc and
Brand Pharma of the commencement thereof, Mallinckrodt plc will be entitled to participate in the Proceeding at its own expense and except as otherwise provided below, to the extent Mallinckrodt plc so wishes, it may assume the defense thereof with
counsel reasonably satisfactory to Indemnitee. After notice from Mallinckrodt plc to Indemnitee of its election to assume the defense of any Proceeding, Mallinckrodt plc shall not be liable to Indemnitee under this Agreement or otherwise for any
Expenses subsequently incurred by Indemnitee in connection with the defense of such Proceeding other than reasonable costs of investigation or as otherwise provided below. Indemnitee shall have the right to employ legal counsel in such Proceeding,
but all Expenses related thereto incurred after notice from Mallinckrodt plc of its assumption of the defense shall be at Indemnitee’s expense unless: (i) the employment of legal counsel by Indemnitee has been authorized by Mallinckrodt
plc, (ii) Indemnitee has reasonably determined that there may be a conflict of interest between Indemnitee and Mallinckrodt plc in the defense of the Proceeding, (iii) after a Change in Control, the employment of counsel by Indemnitee has
been approved by the Independent Counsel, or (iv) Mallinckrodt plc shall not in fact have employed counsel to assume the defense of such Proceeding, in each of which cases all Expenses of the Proceeding shall be borne by Mallinckrodt plc.
Mallinckrodt plc shall not be entitled to assume the defense of any Proceeding (x) brought by or on behalf of Brand Pharma or Mallinckrodt plc, (y) as to which Indemnitee shall have made the determination provided for in (ii) above or
(z) after a Change in Control (it being specified, for the avoidance of doubt, that Mallinckrodt plc may assume defense of any such proceeding described in this sentence with Indemnitee’s consent, provided that any such consent shall not
affect the rights of Indemnitee under the foregoing provisions of this Section 6(b)). 
 (c) Settlement of Claims. Mallinckrodt plc
shall not be liable to indemnify Indemnitee under this Agreement or otherwise for any amounts paid in settlement of any Proceeding effected without Mallinckrodt plc’s written consent, such consent not to be unreasonably withheld; provided,
however, that if a Change in Control has occurred, Mallinckrodt plc shall be liable for indemnification of Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement. Mallinckrodt plc shall not settle any
Proceeding in any manner that would impose any penalty or limitation on Indemnitee without Indemnitee’s written consent. Mallinckrodt plc shall not be liable to indemnify the Indemnitee under this Agreement with regard to any judicial award if
Mallinckrodt plc was not given a reasonable and timely opportunity, at its expense, to participate in the defense of such action; Mallinckrodt plc’s liability hereunder shall not be excused if assumption of the defense of the Proceeding by
Mallinckrodt plc was barred by this Agreement. 
 7. Establishment of Trust. In the event of a Change in Control Mallinckrodt plc shall,
upon written request by Indemnitee, create a trust for the benefit of the Indemnitee (the “Trust”) and from time to time upon written request of Indemnitee shall fund the Trust in an amount sufficient to satisfy any and all Expenses
reasonably anticipated at the time of each such request (a) to be incurred in connection with investigating, preparing for, participating in, and/or defending any Proceeding relating to an Indemnifiable Event and (b) to be indemnifiable
pursuant to this 

  
 - 8 -

 
Agreement. The amount or amounts to be deposited in the Trust pursuant to the foregoing funding obligation shall be determined by the Independent Counsel. The terms of the Trust shall provide
that (i) the Trust shall not be revoked or the principal thereof invaded without the written consent of the Indemnitee, (ii) the Trust shall continue to be funded by Mallinckrodt plc in accordance with the funding obligation set forth
above, (iii) the Trustee shall promptly pay to the Indemnitee all amounts for which the Indemnitee shall be entitled to indemnification pursuant to this Agreement, and (iv) all unexpended funds in the Trust shall revert to Mallinckrodt plc
upon a final determination by the Independent Counsel or a court of competent jurisdiction, as the case may be, that the Indemnitee has been fully indemnified under the terms of this Agreement. The trustee of the Trust (the “Trustee”)
shall be chosen by the Indemnitee. Nothing in this Section 7 shall relieve Mallinckrodt plc of any of its obligations under this Agreement. All income earned on the assets held in the Trust shall be reported as income by Mallinckrodt plc for
federal, state, local, and foreign tax purposes. Mallinckrodt plc shall pay all costs of establishing and maintaining the Trust and shall indemnify the Trustee against any and all expenses (including attorney’s fees), claims, liabilities, loss,
and damages arising out of or relating to this Agreement or the establishment and maintenance of the Trust. 
 8. Non-Exclusivity. The
rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under Mallinckrodt plc’s Articles of Association, the Brand Pharma Organizational Documents, the Brand Pharma Indemnification Agreement, applicable law,
or otherwise. To the extent that a change in applicable law (whether by statute or judicial decision) permits greater indemnification than would be afforded currently under Mallinckrodt plc’s Articles of Association, the Brand Pharma
Organizational Documents, the Brand Pharma Indemnification Agreement, applicable law or this Agreement, it is the intent of the parties that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. 

9. Liability Insurance. For so long as Indemnitee has indemnification rights hereunder or under the Brand Pharma Indemnification Agreement,
Mallinckrodt plc shall maintain an insurance policy or policies providing general and/or directors’ and officers’ liability insurance covering Indemnitee, in accordance with the terms of such policy or policies, to the maximum extent of
the coverage available for any director, officer, secretary or employee, as applicable, of Mallinckrodt plc, provided and to the extent that such insurance is available on a commercially reasonable basis.

10. Exclusions. In addition to and notwithstanding any other provision of this Agreement to the contrary, Mallinckrodt plc shall not be obligated
under this Agreement to make any payment pursuant to this Agreement for which payment is expressly prohibited by law (including, with respect to any director or secretary of Mallinckrodt plc, in respect of any liability expressly prohibited from
being indemnified pursuant to section 200 of the Irish Companies Act 1963 (as amended) (including any successor provisions, “Section 200”), but (i) in no way limiting any rights under section 391 of the Irish Companies Act 1963 (as
amended), and (ii) to the extent any such limitations or prescriptions are amended or determined by a court of a competent jurisdiction to be void or inapplicable, or relief to the contrary is granted, then the Indemnitee shall receive the
greatest rights then available under law. 

  
 - 9 -

 11. Continuation of Contractual Indemnity or Period of Limitations. All agreements and obligations of
Mallinckrodt plc contained herein shall continue for so long as Indemnitee shall be subject to, or involved in, any proceeding for which indemnification is provided pursuant to this Agreement. Notwithstanding the foregoing, no legal action shall be
brought and no cause of action shall be asserted by or on behalf of Mallinckrodt plc or any Affiliate of Mallinckrodt plc against Indemnitee, Indemnitee’s spouse, heirs, executors, or personal or legal representatives after the expiration of
two years from the date of accrual of such cause of action, or such longer period as may be required by the laws of Ireland under the circumstances. Any claim or cause of action of Mallinckrodt plc or its Affiliate shall be extinguished and deemed
released unless asserted by the timely filing and notice of a legal action within such period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, the shorter period shall govern.

 12. Amendment of this Agreement. No supplement, modification, or amendment of this Agreement shall be binding unless executed in
writing by each of the parties hereto. No waiver of any of the provisions of this Agreement shall be binding unless in the form of a writing signed by the party against whom enforcement of the waiver is sought, and no such waiver shall operate as a
continuing waiver. Except as specifically provided herein, no failure to exercise or any delay in exercising any right or remedy hereunder shall constitute a waiver thereof. 
 13. Subrogation. In the event of payment under this Agreement, Mallinckrodt plc shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute
all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable Mallinckrodt plc effectively to bring suit to enforce such rights.

14. No Duplication of Payments. Mallinckrodt plc shall not be liable under this Agreement to make any payment in connection with any claim made by
Indemnitee to the extent Indemnitee has otherwise received payment (under any insurance policy, Mallinckrodt plc’s Articles of Association, the Brand Pharma Organizational Documents, the Brand Pharma Indemnification Agreement or otherwise) of
the amounts otherwise indemnifiable hereunder. 
 15. Obligations of Mallinckrodt plc. In the event a Proceeding results in a judgment in
Indemnitee’s favor or otherwise is disposed of in a manner that allows Mallinckrodt plc to indemnify Indemnitee in connection with such Proceeding under the Articles of Association of Mallinckrodt plc as then in effect, Mallinckrodt plc will
provide such indemnification to Indemnitee and will reimburse Brand Pharma for any indemnification or Expense Advance previously made by Brand Pharma in connection with such Proceeding. 
 16. Binding Effect. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect
successor by purchase, merger, consolidation, or otherwise to all or substantially all of the business and/or assets of Mallinckrodt plc), assigns, spouses, heirs, and personal and legal representatives; provided, however, that Brand Pharma shall be
a beneficiary of, and have the right to enforce, Section 15 hereof. Mallinckrodt plc shall require and cause any successor thereof (whether direct or indirect by purchase, merger, consolidation, or otherwise) to all, substantially all, or a
substantial part, of the business and/or assets of Mallinckrodt plc, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that
Mallinckrodt plc would be required to 

  
 - 10 -

 
perform if no such succession had taken place. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified
capacity pertaining to an Indemnifiable Event even though he may have ceased to serve in such capacity at the time of any Proceeding or is deceased and shall inure to the benefit of the heirs, executors, administrators, legatees and assigns of such
a person.
 17. Severability. If any provision (or portion thereof) of this Agreement shall be held by a court of competent jurisdiction
to be invalid, void, or otherwise unenforceable, the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of this Agreement (including, without limitation,
each portion of this Agreement containing any provision held to be invalid, void, or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held
invalid, void or unenforceable.
 18. Governing Law. This Agreement shall be governed by and construed and enforced in accordance with
the laws of Ireland applicable to contracts made and to be performed in such State without giving effects to its principles of conflicts of laws.
 19. Notices. All notices, demands, and other communications required or permitted hereunder shall be made in writing and shall be deem to have been duly given if delivered by hand, against receipt,
or mailed, postage prepaid, certified or registered mail, return receipt requested, and address to Mallinckrodt plc at: 

Mallinckrodt plc 

Mulhuddart 

Damastown 

Dublin 15 

Ireland 
 Attn:
General Counsel 
 Facsimile: +352-266-379-92 
 and 
 Mallinckrodt 

675 James S. McDonnell Blvd. 
 Hazelwood, MO 63042 
 Attn: General Counsel 

Facsimile: 314-654-5366 
 And to
Indemnitee at: 
 Notice of change of address shall be effective only when given in accordance with this Section. All notices complying with
this Section shall be deemed to have been received on the date of hand delivery or on the third business day after mailing. 

  
 - 11 -

 20. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 

  
 - 12 -

 IN WITNESS WHEREOF the parties have executed this Deed of Indemnification as a deed with the
intention that it be delivered on the date first written above. 
  

					
	GIVEN under the common seal of	  	  

	 MALLINCKRODT PUBLIC LIMITED COMPANY
 and DELIVERED as a DEED
	  	Duly Authorised Signatory
		
		  	  

		  	Duly Authorised Signatory
			
	 SIGNED AND DELIVERED as a deed
 by [INSERT NAME OF INDEMNITEE]
 in the presence of:
	  	  
	  	
	  	Indemnitee	  	

							
				
	  
	 		  		  	
	 Witness
  

Name of Witness:
  
 Address of Witness:
  

Occupation of Witness:
	  		  	

  
 - 13 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]